By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162


SEARCH JOBS


Industry
Services
Healthcare






Company News
Agendia BV’s Mammaprint Recommended By ASCO Breast Cancer Guideline In Focused Update Based On Landmark MINDACT Trial Data 7/11/2017 7:21:31 AM
Agendia BV's MammaPrint Recommended By The 2017 St. Gallen International Breast Cancer Guidelines In Significant Update 7/6/2017 8:42:30 AM
Agendia BV Release: Mammaprint Late Recurrence (20yr) Low Risk Result Identifies Breast Cancer Patients With 97% Survival At 20-Years With Limited Endocrine Therapy Treatment 6/29/2017 11:03:58 AM
Agendia BV Release: Three New Studies Presented At ASCO Annual Meeting Demonstrate Benefits Of Mammaprint In Aiding Individualized Treatment Management For Early-Stage Breast Cancer Patients 6/13/2017 7:54:45 AM
Agilent (A) And Agendia BV Sign Agreement On Molecular Cancer Diagnostics 6/8/2017 9:34:40 AM
Agendia BV’s MammaPrint Now Included In Blue Shield Of California Coverage For Breast Cancer Patients 6/2/2017 7:57:45 AM
Agendia BV’s MammaPrint Now Included In First Coast Coverage For Medicare Breast Cancer Patients In Florida, Puerto Rico And The Virgin Islands 5/2/2017 7:37:15 AM
Agendia BV Appoints Patrick J. Balthrop Sr., Former CEO Of Luminex (LMNX), As Chairman 4/20/2017 11:24:21 AM
Agendia BV Appoints Patrick J. Balthrop Sr., Former CEO Of Luminex (LMNX), As Chairman 4/13/2017 7:21:39 AM
European Group On Tumour Markers (EGTM) Updated Guidelines Recommend Agendia BV's Mammaprint Test With Highest Level 1A Clinical Evidence 3/22/2017 6:47:32 AM
12345678910...
//-->